Education
About Us
Working with TipRanks
Follow Us
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: 8.54%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress with FDA approvals and strong trial retention. Financial stability and expansion opportunities in additional indications were also emphasized. However, there were delays in timeline for topline data and a reduction in trial size, indicating some operational adjustments.Company Guidance
During the Ocular Therapeutix Fourth Quarter 2024 Earnings Conference Call, significant updates were shared regarding the registrational program for AXPAXLI in wet AMD. The FDA approved an amendment to the SOL-1 study's special protocol agreement, allowing redosing at weeks 52 and 76, aiming to secure a six to 12-month dosing label. This amendment is expected to enhance the drug's potential as a long-lasting treatment option. As a result, topline data for SOL-1 is now anticipated in the first quarter of 2026. The SOL-R study was optimized, reducing its size from 825 to 555 subjects while maintaining a robust statistical power of 90%. This change aims to accelerate the timeline for reporting data and regulatory submission. The company reported strong financial health with a cash balance of $392 million, projecting sufficient funding into 2028 without plans to raise additional capital in 2025.FDA Approval for Amendment to SOL-1 Protocol
Received FDA approval for an amendment in SOL-1 to incorporate redosing at weeks 52 and 76, potentially increasing label flexibility to every six to 12 months.
Completion of SOL-1 Randomization
SOL-1 trial completed randomization ahead of schedule in December 2024 with 344 subjects.
Strong Patient Retention in SOL-1
Reported exceptional patient retention in SOL-1, with most rescue treatments aligning with prespecified criteria.
Financial Position and Cash Runway
Cash balance of $392 million as of December 31, 2024, with a cash runway into 2028.
Expansion Opportunities in NPDR and DME
Positive results from the HELIOS trial in NPDR and DME, with FDA feedback on clinical trial design expected in the first half of 2025.
---
OCUL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OCUL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $7.14 | $5.92 | -17.09% |
| Nov 14, 2024 | $10.60 | $9.92 | -6.42% |
| Aug 07, 2024 | $7.89 | $8.37 | +6.08% |
| May 07, 2024 | $5.93 | $5.75 | -3.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ocular Therapeutix (OCUL) report earnings?
Ocular Therapeutix (OCUL) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Ocular Therapeutix (OCUL) earnings time?
Ocular Therapeutix (OCUL) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCUL EPS forecast?
OCUL EPS forecast for the fiscal quarter 2025 (Q1) is -0.29.
---